Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study

2016 ◽  
Vol 24 (2) ◽  
pp. 412-418 ◽  
Author(s):  
L. H. Markvardsen ◽  
S. H. Sindrup ◽  
I. Christiansen ◽  
N. K. Olsen ◽  
J. Jakobsen ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Controlled Trial ◽  
Subcutaneous Immunoglobulin ◽  
First Line ◽  
Randomized Controlled ◽  
First Line Therapy ◽  
Line Therapy ◽  
Inflammatory Demyelinating Polyneuropathy ◽  
Treatment Naïve

scholarly journals Efficacy of two-week quadruple bismuth treatment versus levofloxacin concomitant Helicobacter Pylori infection regimen as empirical first-line therapy Syrian patients. A randomized controlled trial.

2020 ◽  
Author(s):  
Marouf Muhammad Alhalabi ◽  
Mohammed Waleed Alassi ◽  
Kamal Alaa Eddin ◽  
Khaled Cheha
Keyword(s):  
Randomized Controlled Trial ◽  
Helicobacter Pylori ◽  
Controlled Trial ◽  
Helicobacter Pylori Infection ◽  
First Line ◽  
Open Label ◽  
Randomized Controlled ◽  
First Line Therapy ◽  
Line Therapy

Abstract Introduction: Antibiotic-resistant reduces the efficacy of conventional triple therapy for Helicobacter Pylori infections worldwide, lead to varying treatment protocols according to locations.Aim: Primary outcome was eradication rates of bismuth quadruple (BQ) and levofloxacin concomitant (LC) as empirical first-line treatment by intention to treat (ITT) in a referral hospital in Syria.Design: an open‑label parallel blind randomized controlled trial.Materials and Methods: We randomly assigned seventy-eight naïve who tested positive for Helicobacter Pylori gastric infection, with a 1:1 ratio to receive either BQ (bismuth subsalicylate 524 mg four times daily, doxycycline 100 mg, tinidazole 500 mg, and esomeprazole 20 mg, each twice daily for two weeks), or LC (levofloxacin 500 mg daily, tinidazole 500 mg, amoxicillin 1000 mg, and esomeprazole 20 mg each twice daily for two weeks). We confirmed Helicobacter Pylori eradication by stool antigen test by eight weeks.Results: Thirty-nine patients were allocated in each group. In the BQ group, thirty-eight patients completed the follow-up, thirty patients were cured. While in the LC group, thirty-nine completed the follow-up, thirty-two patients were cured. The ITT eradication rates of the BQ and LC groups were 76.92%, and 82.05%, respectively. Odds ratio with 95% confidence interval according to ITT was 1.371 [0.454-4.146]. We didn’t report serious adverse effects.Conclusions:Both therapy regimens had acceptable rates of eradication. we suggest using both regimens as empirical first-line therapy in the treatment of Helicobacter Pylori infection in the Syrian population.Clinicaltrial.gov, NCT04348786

scholarly journals Comparison of DRPM and MEPM as the first-line therapy in FN patients with acute leukemia: A randomized, controlled trial

2016 ◽  
Vol 27 ◽  
pp. vii87
Author(s):  
Tatsuo Oyake ◽  
Yuka Fujisawa ◽  
Norifumi Sugawara ◽  
Takahiro Mine ◽  
Yasuhiko Tsukushi ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Acute Leukemia ◽  
Controlled Trial ◽  
First Line ◽  
Randomized Controlled ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Grupo Espanol de Estudio Tratamiento y otras Estrategias Experimentales en Tumores Solidos (SOLTI)

2006 ◽  
Vol 9 (S1) ◽  
pp. 439-441
Author(s):  
Keyword(s):  
Clinical Trials ◽  
Controlled Trial ◽  
Metastatic Breast ◽  
Phase Iii ◽  
List Type ◽  
First Line ◽  
Randomized Controlled ◽  
First Line Therapy ◽  
Line Therapy ◽  
Current Contact

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Grupo Espanol de Estudio Tratamiento y otras Estrategias Experimentales en Tumores Solidos (SOLTI). Clinical trials include: A phase III randomized, controlled trial of myocet, trastuzumab and paclitaxel versus trastuzumab and paclitaxel for first line therapy of metastatic breast cancer.

Sign in / Sign up

Export Citation Format

Share Document